English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, March 28, 2022
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得
Tuesday, March 22, 2022
エーザイとバイオジェン、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会(AD/PD(TM) 2022)において発表
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
Wednesday, March 16, 2022
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更
Tuesday, March 15, 2022
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
Friday, March 11, 2022
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting
Wednesday, March 9, 2022
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Monday, March 7, 2022
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575